These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22896662)

  • 1. Revisiting the complexity of the ovarian cancer microenvironment--clinical implications for treatment strategies.
    Musrap N; Diamandis EP
    Mol Cancer Res; 2012 Oct; 10(10):1254-64. PubMed ID: 22896662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the tumour microenvironment in ovarian cancer.
    Hansen JM; Coleman RL; Sood AK
    Eur J Cancer; 2016 Mar; 56():131-143. PubMed ID: 26849037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging growth factor receptor antagonists for ovarian cancer treatment.
    Bonilla L; Oza A; Lheureux S
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):1-16. PubMed ID: 29528256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of early investigational therapies for chemoresistant ovarian cancer.
    Marchetti C; Ledermann JA; Benedetti Panici P
    Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
    Jackson AL; Eisenhauer EL; Herzog TJ
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
    Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
    Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
    Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.
    Chen SS; Michael A; Butler-Manuel SA
    Discov Med; 2012 Jan; 13(68):7-17. PubMed ID: 22284780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
    Wang Z; Fu S
    Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morusin induces paraptosis-like cell death through mitochondrial calcium overload and dysfunction in epithelial ovarian cancer.
    Xue J; Li R; Zhao X; Ma C; Lv X; Liu L; Liu P
    Chem Biol Interact; 2018 Mar; 283():59-74. PubMed ID: 29421517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor.
    Lungchukiet P; Sun Y; Kasiappan R; Quarni W; Nicosia SV; Zhang X; Bai W
    J Steroid Biochem Mol Biol; 2015 Apr; 148():138-47. PubMed ID: 25448740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapies in epithelial ovarian cancer.
    Teoh DG; Secord AA
    Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial ovarian cancer: focus on targeted therapy.
    Pliarchopoulou K; Pectasides D
    Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer.
    Campbell N; Greenaway J; Henkin J; Petrik J
    Mol Cancer Ther; 2011 Oct; 10(10):1876-85. PubMed ID: 21844212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Wang X; Zhu Q; Lin Y; Wu L; Wu X; Wang K; He Q; Xu C; Wan X; Wang X
    Br J Cancer; 2017 Oct; 117(9):1371-1382. PubMed ID: 28898232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer.
    Longoria TC; Eskander RN
    Recent Pat Anticancer Drug Discov; 2015; 10(2):133-44. PubMed ID: 25938471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets--where are we now?
    Syrios J; Banerjee S; Kaye SB
    Anticancer Res; 2014 May; 34(5):2069-77. PubMed ID: 24778008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.